• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP IMUFLEX BLOOD BAG SYSTEM; BB*LGQ456E6 IMUFLEX WB-SP CPD/SAGM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP IMUFLEX BLOOD BAG SYSTEM; BB*LGQ456E6 IMUFLEX WB-SP CPD/SAGM Back to Search Results
Catalog Number 1BBLGQ456E6
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 02/24/2023
Event Type  malfunction  
Event Description
The customer would like the run data file investigated to determine a possible cause for the elevated white blood cell (wbc) content in the platelet product.There was not a transfusion recipient or patient involved at the time of the residual wbc testing, therefore no patient information is reasonably known at the time of the event.This product is not available within the us, but this report is being filed due to an alleged failure that could occur on a similarly marketed device platform cleared for use by the fda.The platelet collection set is not available for return because it was discarded by the customer.
 
Manufacturer Narrative
Investigation: the set concerned was not available and we therefore conducted the following investigations based on the information provided.In regard to the filter used for the product in question, the filter media is formed (membrane making process) followed by the cutting process, warming process, staking and punching process, and housing assembling process.Review of the manufacturing record of the lot number in question was performed.There was no equipment trouble causing the issue concerned and it was confirmed that the equipment had operated properly, and no anomalies had been observed.The manufacturing records regarding particulate removal rates of filter membranes that were likely to be related to filtration performance were reviewed.It was confirmed that all filter membranes conformed to all standards.Release testing, including a visual inspection and other items, is performed on the product concerned on a sample basis.We reviewed each testing and inspection record of the lot number in question and confirmed that there were no anomalies in all testing items.The product conformed to the standards.Three sets of retained samples of the lot number concerned were visually inspected.There were no abnormalities, such as tubing occlusion and blockage, in their appearances.Root cause: from the above-mentioned investigation results, we did not observe any abnormalities in the manufacturing process of the lot number concerned.As mentioned in the investigation results above, the filter membranes of the product concerned consist of a rough-pore pre-membrane (the first filter membrane) and minute-pore main membranes (the second through eighth filter membranes).According to the data at the time of designing of the product in question, there is a possibility of white blood cell contamination when the particulate removal rates are low.However, as mentioned above, the particulate removal rates of the lot number concerned were within the standards and did not show a low tendency.Therefore, we were not able to identify the cause of the issue.Leukoreduction failure is commonly caused by the following factors: 1) blood characteristics of donors there is a possibility of leukoreduction failure due to blood characteristics of donors.2) pressure loaded on filter membranes for some reason, where a physical stress on filter membranes is greater than what is expected, trapped white blood cells are pushed out of the filter membranes and may result in leukoreduction failure.For the prevention of leukoreduction failure, the instructions for use (ifu) of the product state: "[caution] do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood".Based on the investigation results of similar issues which we received in the past, a general cause of leukocyte reduction failure can be cited that pressure was applied to the collection bag or the filter during the filtration process of the collected blood.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMUFLEX BLOOD BAG SYSTEM
Type of Device
BB*LGQ456E6 IMUFLEX WB-SP CPD/SAGM
Manufacturer (Section D)
TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP
fujinomiya 418-0 004
JA  418-0004
Manufacturer (Section G)
TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP
818 misonodaira
fujinomiya 418-0 004
JA   418-0004
Manufacturer Contact
makoto yoshikawa
818 misonodaira
fujinomiya 418-0-004
JA   418-0004
MDR Report Key16619273
MDR Text Key312423791
Report Number9681839-2023-00019
Device Sequence Number1
Product Code CAK
Combination Product (y/n)N
Reporter Country CodeCO
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/27/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number1BBLGQ456E6
Device Lot Number220602AF
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 03/02/2023
Initial Date FDA Received03/27/2023
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-